compound semaglutide dosing chart Dosage Chart: Complete Guide FAQs About Wegovy® | Wegovy®

Based on typical FDA review timelines and the current progress of trials, analysts project: Phase 3 trial completion: Late 2025 to early 2026 FDA submission: First half of 2026 Potential FDA approval: Q3 2026 to Q1 2027 Commercial availability: 2-3 months post-approval The FDA has not granted any special designations (Breakthrough Therapy, Fast Track) for Retatrutides obesity indication, which may mean standard review timelines apply

No rinsing required

Some patients receiving compounded versions have required urgent medical evaluation due to dosing inconsistencies or contamination

Gut-related applications often show improvement within 1-3 weeks

Your body is encountering a new medication and adjusting to different signals about hunger and digestion